The latest announcement is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Ltd. has announced a change in its company secretary, with Ms. Leah Liu resigning and Mr. King Hang Yeung being appointed as the new joint company secretary effective April 15, 2025. This change is part of the company’s ongoing efforts to strengthen its corporate governance. Additionally, the company has clarified an error in the calculation of restricted share units (RSUs) under its Pre-IPO Employee Stock Ownership Plan (ESOP), which impacts the reported outstanding and available shares as of June 30, 2024. These adjustments are crucial for maintaining transparency and accuracy in the company’s financial reporting, which is vital for stakeholders’ trust.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the fields of oncology, autoimmune disorders, and infectious diseases. The company aims to address critical unmet medical needs in the Asian market, leveraging its strong pipeline of innovative therapies.
YTD Price Performance: 3.82%
Average Trading Volume: 5,217,569
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.41B
Find detailed analytics on 1952 stock on TipRanks’ Stock Analysis page.